<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985594</url>
  </required_header>
  <id_info>
    <org_study_id>FF-2013-407</org_study_id>
    <nct_id>NCT01985594</nct_id>
  </id_info>
  <brief_title>Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial</brief_title>
  <acronym>UTROGESTAN</acronym>
  <official_title>STUDY ON EFFICACY OF UTROGESTAN AS TOCOLYSIS FOR PRETERM LABOR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>nor zila hassan malek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RESEARCH HYPOTHESIS

      -Incidence of preterm delivery is lower in women treated with oral micronized progesterone
      (Utrogestan) as acute tocolysis agent compare to Nifedipine group with fewer maternal side
      effect
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>latency period interval between time of tocolysis and delivery</measure>
    <time_frame>24 hours up to 7 days</time_frame>
    <description>delivery less than 24 hours of tocolysis,delivery less than 48 hours of tocolysis, delivery less than 7 days of tocolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>34 weeks of gestational age</time_frame>
    <description>delivery less than 34 weeks of gestation, delivery more than or at 34 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal outcome</measure>
    <time_frame>24 hours</time_frame>
    <description>Birth weight (kg),cord blood acidity, need for neonatal intensive care unit admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal side effect</measure>
    <time_frame>30 minutes up to 48 hours</time_frame>
    <description>Palpitation,Headache, Nausea/Vomiting, Hypotension, Dyspnea, Jaundice, Pruritus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Utrogestan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral tablet Utrogestan 400mg daily for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>utrogestan</intervention_name>
    <description>Oral Tablet Utrogestan 400 mg daily for 2 days</description>
    <arm_group_label>Utrogestan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days</description>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Singleton pregnancy women between 22 and 34 weeks of gestation who presented with
        threatened preterm labor.

        Exclusion Criteria:

          -  Multiple pregnancies

          -  Women with Preterm Prelabour Rupture of Membrane

          -  Fetal death

          -  Women with bad obstetric history

          -  Women with history of cervical incompetence

          -  Contraindication to Nifedipine such as cardiovascular disease, hyperthyroidism, severe
             pre eclampsia or to Utrogestan

          -  Maternal or fetal indication for immediate delivery, such as fetal distress, bleeding
             placenta previa, abruption placenta

          -  Contraindication for tocolysis, for example severe pre eclampsia, intrauterine growth
             restriction, fetal anomaly, chorioamnionitis, significant antepartum haemorrhage

          -  Cervical dilatation of 3cm or more

          -  Patients with previous tocolytic treatment during this pregnancy

          -  Women who refuse to participate in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nor azlin mohamed ismail</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University of Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>nor zila hassan malek</last_name>
    <phone>60139823219</phone>
    <email>nzhm_dr@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Obstetric and Gynaecology Department, National University of Malaysia Medical Centre</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>national university of malaysia medical centre</last_name>
      <phone>60391455950</phone>
    </contact>
    <investigator>
      <last_name>nor zila hassan malek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>nor azlin mohamed ismail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>November 10, 2013</last_update_submitted>
  <last_update_submitted_qc>November 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>nor zila hassan malek</investigator_full_name>
    <investigator_title>medical officer</investigator_title>
  </responsible_party>
  <keyword>preterm labor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

